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Background: Obesity is a risk factor for insulin resistance (IR) and metabolic disease.
Objective: To examine potential metabolic pathways linking childhood weight status
to adolescent IR and metabolic risk.
Methods: Participants were 600 low- to middle-income Chilean adolescents from a
cohort studied since infancy as part of an iron deficiency anemia preventive trial and
follow-up study. We examined body mass index z-score at 10 y (BMIz-10y) and
blood pressure, total fat, and fasting glucose, adiponectin to leptin ratio (A:L), ghrelin,
and HOMA-IR at 16 y. A total count for metabolic risk factors (MRF) was calculated
using the International Diabetes Federation criteria. We used path analysis to esti-
mate pathways and model indirect effects from BMIz-10y, controlling for child age
and sex and maternal body mass index (BMI).
Results: Participants were 54% male; mean BMIz-10y of 0.53 (SD = 1.02); mean MRF of
1.3 (SD = 0.9); mean HOMA-IR of 1.8 (SD = 1.3). Path analysis showed that BMIz-10y
directly and indirectly related to increased MRF via A:L and HOMA-IR. Ghrelin was not in
the metabolic pathway from BMIz-10y to MRF but was related to MRF via HOMA-IR.
Conclusion: These results elucidate metabolic pathways involving child weight status,
IR and metabolic risk in adolescents. Childhood BMI was an indirect risk factor for
adolescent cardiometabolic risk via several pathways that involved BMI, appetite hor-
mones, markers of inflammation, and insulin resistance during adolescence. Findings
illustrate the adverse effect that childhood obesity has on adolescent health out-
comes, which sets precedence for health outcomes over the life course.
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1 | INTRODUCTION
Childhood is a critical period that can influence health throughout the
life course. The impact of childhood weight status on metabolic health
extends into adulthood and can last a lifetime. This is in line with the
developmental origins of health and disease hypothesis.1 There is
mounting evidence to suggest that obesity impacts metabolic risk
through insulin resistance (IR),2 yet the mechanisms are unclear.
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A better understanding of the metabolic mechanisms that connect
childhood weight status to later metabolic health is needed to
improve clinical strategies that can reduce or prevent health complica-
tions throughout the life course.
Studies of adults have established pathways that connect obesity
to energy intake and appetite hormone regulation such as ghrelin and
leptin. The function of ghrelin is closely related to feeding behavior
and the metabolic function of adipokines (such as leptin and
adiponectin). Ghrelin functions as an appetite-stimulatory signal, with
pre-meal/preprandial increases and postprandial decreases.3 Levels of
ghrelin show diurnal variations and decrease with food intake, increas-
ing age, body mass index (BMI), glucose and insulin, and are higher in
females than males.3 Ghrelin also has anti-inflammatory effects.3,4
Conversely, leptin functions as a feedback mechanism that rises post-
meal (postprandial) and signals the brain to inhibit food intake to regu-
late body weight and energy balance/homeostasis. Levels of leptin
have been found to be higher in individuals with increased weight sta-
tus and body fat.5 Together leptin and ghrelin exert opposing effects
on appetite, playing a central role in energy balance.
Insulin and adiponectin are interrelated and both play a protective
role in the development of obesity.6 Insulin is released into the blood-
stream shortly after food intake to lower blood glucose and inhibits
appetite similarly to leptin. Adiponectin is secreted by the adipose tis-
sue.7 Plasma adiponectins are correlated negatively with insulin resis-
tance.7 Moreover, researchers have found low adiponectin levels
among individuals with type 2 diabetes, even after adjusting for body
weight.8
Ghrelin and adipokines (leptin and adiponectin) are related to car-
diovascular effects in adults. Leptin is known for its pro-inflammatory
function, adiponectin for its anti-inflammatory function, and ghrelin
for its role on endocrine pancreatic function, glucose metabolism, and
positive vasodilatory effects.8 Most studies have examined these fac-
tors in isolation, with few studies examining the interrelationships
between these factors, and in relation to metabolic risk.8 Schutte and
colleagues examined the relation of adipokines to metabolic risk
(N = 115 women ages 29-42) and found a positive relationship
between leptin with insulin resistance and a negative relationship with
ghrelin and insulin resistance.8 Others have found that leptin is posi-
tively correlated with BMI but that adiponectin is correlated with
decreased BMI in children.9 More recently, the ratio of leptin to
adiponectin (L:A) was used as a sensitive marker for detecting early
metabolic disturbance and insulin resistance.10
From previous studies of adults, Lucasson et al. developed a
framework to examine how adult lifestyle behaviors, especially sleep
loss, lead to the development of chronic disease via endocrine mecha-
nisms that stimulate appetite, decrease energy expenditure, and
increase insulin resistance.7 In the current study, we applied
Lucasson's framework to elucidate mechanisms connecting childhood
weight status to metabolic risk in adolescence (Figure 1).
The risk for metabolic syndrome is increasingly a problem among
children and adolescents. Therefore, it is essential to understand the
mechanisms by which childhood weight status can impact adolescent
health. This study aimed to explore potential pathways linking
childhood weight status at 10 y to metabolic risk in a cohort of
679 Chilean adolescents. We hypothesized that childhood weight sta-
tus would be related to an increase in the number of metabolic risk
factors through biomarkers of appetite hormone regulation (ghrelin,
leptin, and adiponectin) and insulin resistance. We also hypothesized
that insulin resistance would be partially mediate the relationship
between ghrelin, L:A, and metabolic risk.
2 | METHODS
2.1.1 | Study cohort and setting
Participants were of low- to middle-income backgrounds in Santiago,
Chile. Adolescents and their mothers (or caregivers) were participants
in an ongoing longitudinal cohort study, which began as an iron ane-
mia deficiency (IDA) preventive trial between 1991 and 1996.11
Healthy infants (singleton, full-term births, born via routine vaginal
delivery, had birth weight ≥ 3.0 kg, who had no major complications,
no chronic illness, and required no iron therapy) were recruited from
four contiguous low- to middle-income, working-class, communities
located in the southern part of Santiago (n = 1657). These neighbor-
hoods were selected based on their close proximity to the research
site, the Institute for Nutrition and Food Technology (INTA), Univer-
sity of Chile. Details about the enrollment and trial have been previ-
ously described.12 The cohort was evaluated at 5, 10, and 16 y. At 5 y,
the available budget allowed evaluation of two of the three infancy
randomization groups. We assessed those who had been assigned to
iron-supplementation or no iron added (n = 888). Thus, those seen at
the 5 y follow-up are the most studied group and were invited to par-
ticipate in an adolescent study of risk for obesity and cardiovascular
F IGURE 1 An adapted and simplified schematic representation of
Lucasson's putative pathways linking lifestyle to obesity and diabetes,
via endocrine mechanisms that stimulate appetite, decrease energy
expenditure, and increase insulin resistance. The direction of change
(an increase or decrease) of each mechanism due to poor lifestyle,
such as sleep loss; decreased leptin (lep) and increased ghrelin (ghr)
could stimulate appetite; increased appetite could increase obesity
risk; decreased adiponectin could increase insulin resistance, and in
turn increase diabetes risk
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risk factors between 2005 and 2012 (n = 679).12 Participants in the
adolescent follow-up of cardiovascular risk were similar to participants
of the original infancy study with respect to the following variables:
birth weight and length, sex, maternal and paternal total years of edu-
cation, maternal age, number of stressors reported in infancy, and
maternal CES-D in infancy (all P > .05). The adolescent group was
breastfed exclusively for slightly longer (118 vs 100 d) and ended any
breastfeeding slightly later than those in the entire infancy cohort
(244 vs 227 d), both P < .05.
2.1.2 | Study design
For this study, we used data collected at two time points between
2005 and 2012 (n = 679). This study was approved by the Institutional
Review Boards at INTA, the University of Michigan, and the Univer-
sity of California, San Diego.
2.1.3 | Assessment of weight status
At 10 y, height (cm) and weight (kg) were measured by a trained nurse
at INTA. Standardized procedures (27) were used to measure weight
to the closest 0.1 kg and height to the closest 0.1 cm. Measurements
were taken twice, with a third measurement if the difference between
the first two exceeded 0.3 kg for weight and 0.5 cm for height. Mater-
nal height and weight were also measured during the child's visit.
Anthropometry was measured in adolescence (between 16 and
18 y) by two trained physicians. Weight and height were assessed in
duplicate with a Precision Hispana scale and a stadiometer accurate
to 0.1 kg and 0.1 cm, respectively. Participants were measured with-
out shoes, wearing underwear, in the Frankfurt position. Waist cir-
cumference and blood pressure were also measured twice. If the first
and second measurements did not match for height, weight, or blood
pressure (BP), the measurements were repeated. All participants were
measure for BP according to standard protocols.
BMI z-scores at 10 y and in adolescence were calculated using
CDC BMI percentiles, which consider age and sex, and analyzed as
continuous variables.
2.1.4 | Blood assays
After an overnight fast, a morning blood sample (between 800 and
1000) was collected for the measurement of fasting glucose, lipids, a
measure of insulin resistance and appetite hormones. Fasting serum lep-
tin concentration (1 ng/mL sensitivity) was measured using the Sand-
wich Enzyme Immunoassay kit (DRG International, Inc., USA) and
adiponectin using ELISA R&D Systems (Minneapolis, MN, USA). Leptin
to adiponectin ratios were then calculated. Commercial radioimmuno-
assay kits were used to measure ghrelin (Phoenix Pharmaceuticals,
Inc., Burlingame, CA, USA) and insulin (Diagnostic Products Corpora-
tion, Los Angeles, CA, USA). Glucose was measured using the
enzymatic-calorimetric kit (QCA S.A. Amposta, Spain). HOMA-IR was
then calculated as [glucose*insulin]/405. Concentration of high den-
sity lipoprotein and triglyceride levels were measured using the analyt-
ical methodology dry kit (Vitros, Johnson & Johnson, Clinical
Diagnostics, Inc.). Glucose was measured using the enzymatic-
calorimetric kit (QCA S.A. Amposta, Spain).
2.2 | Study variables
2.2.1 | Independent variable
Childhood weight status. We examined BMI z-scores at 10 y (BMIz-
10y) as the independent risk factor for metabolic risk.
2.2.2 | Dependent variable
Metabolic risk factors. We examined the number of metabolic risk fac-
tors for the metabolic syndrome as the dependent variable. We used
the IDF criteria to compute the number of MR factors using the fol-
lowing five risk factors: elevated BP, a low high density lipoprotein
cholesterol level, a high triglyceride level, a high fasting glucose level,
and abdominal obesity, adjusted for age and sex.13 BP > 90th percen-
tile was defined as a systolic or diastolic BP > 90th percentile for age,
sex, and height.
2.2.3 | Mediators
Appetite regulation hormones and inflammation. We examined bio-
markers of appetite regulation and inflammation at 16 y as mediators
of the relationship between BMIz-10y and metabolic risk factors. This
included ghrelin [pg/mL], L:A ratio [μg/mL], and HOMA-IR.
2.2.4 | Covariates
We controlled for child age and sex and maternal BMI at the
10y wave.
2.2.5 | Analytic framework
We tested pathways between BMIz-10y to metabolic risk, which was
informed by the framework best described by Lucasson et al.
(Figure 1) and illustrated in Figure 2.
2.2.6 | Analytic plan
Sample characteristics, including BMI and HOMA-IR, were examined
for the total sample and by sex. Appetite hormones and energy
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regulators were examined by sex and using the 95th percentile cut-
off for obesity. Chi-square tests were considered significant at
P < .05. All descriptive statistics were performed using IBMI SPSS 21.
The main analytic plan involved longitudinal analysis using data
from the 10y and 16y waves. We used path analysis to explore path-
ways between BMIz-10y and metabolic risk factors. The model tested
three metabolic pathways: 1) BMIz-10y à ghrelin à number of meta-
bolic risk factors; 2) BMIz-10y à L:A à HOMA-IR à number of met-
abolic risk factors; and 3) BMIz-10y à L:A à number of metabolic
risk factors. The model also tested the direct effect of BMIz-10y on
metabolic risk factors at 16 y. First, we conducted a multiple group
analysis to account for sex differences, given the empirical evidence
that leptin and ghrelin levels differ by sex. Second, because models
were similar for females and males, we conducted a one-sample path
analysis, which controlled for the relationships of sex and age with
ghrelin, L:A, HOMA-IR and metabolic risk, and maternal BMI with
BMIz-10y. For parsimony, the final model controlled for covariates
with P < .20, which included relationships of sex with ghrelin, L:A,
HOMA-IR and metabolic risk, age with ghrelin and HOMA-IR, and
maternal BMI with BMIz-10y. All path analyses was performed using
MPlus 7 software (Muthén & Muthén, Los Angeles, CA), with the full
maximum likelihood function. The model fit was determined by using
the following indices: Confirmatory fit index (CFI ≤ 0.90); root mean
square error of approximation (RMSEA ≤ 0.06); and standardized root
mean square residual (SRMR ≤ 0.08); and a significance level of
P < .05. Mediation was tested using the INDIRECT command to esti-
mate indirect effects, using MPlus.
3 | RESULTS
3.1.1 | Sample characteristics
Table 1 summarizes the characteristics of the study cohort. Adoles-
cents averaged 16.8 (SD 0.26) y of age; 54% were male; and the mean
BMIz was 0.52. Adipokines were significantly higher among females
than males: leptin (female: 19.07, SD 14.58; male: 5.93, SD 9.24;
P < .001), and L:A (female: 2.01, SD 2.32; male: 0.74, SD 1.17;
P < .001). There were also sex differences for the following metabolic
risk factors: elevated BP (female: 4%, male: 11%, P < .001); low HDL
(female: 75%, male: 64%, P < .002); elevated glucose (female 7%,
male: 1%, P < .03); and abdominal obesity (female: 51%; males: 13%;
P < .001). BMIz-16y was correlated with BMIz-10y (ρ = 0.60,
P < .001) and metabolic risk factors (ρ = 0.60, P < .001).
3.1.2 | Main results
Model fit for the path analysis for the total sample was acceptable
(CFI = 0.99; RMSEA = 0.03; and SRMR = 0.03). Findings for males and
females were similar; therefore, we present findings for the total sam-
ple illustrated in Figure 3.
F IGURE 2 Illustration of the
potential pathways linking child
weight status at age 10 to risk for
metabolic syndrome at age 16
TABLE 1 Sample characteristics of the cohort (total sample and




n = 322 Male n = 357
Age at 16 y
evaluation
16.8 (0.3) 16.9 (0.3) 16.8 (0.3)
10 y BMI z-score 0.52 (1.02) 0.68 (0.95) 0.83 (0.95)
16 y BMI z-score* 0.76 (0.95) 0.61 (0.94) 0.45 (1.08)
Ghrelin 238 (146) 251 (154) 227 (137)
Leptin*** 12.17 (13.74) 19.07 (14.58) 5.93 (9.24)
Adiponectin 11.29 (5.36) 10.28 (4.95) 12.39 (5.57)
L:A*** 1.35 (1.91) 2.01 (2.32) 0.74 (1.17)
HOMA-IR 1.79 (1.32) 1.80 (1.23) 1.78 (1.40)
Elevated
BP, %, n**
7%, 50 4%, 12 11%, 38
Low HDL, %, n** 69%, 471 75%, 242 64%, 229
Elevated TG, %, n 8%, 53 8%, 24 8%, 29
Elevated
glucose, %, n*




30%, 205 51%, 158 13%, 47
No. of metabolic
risk factors
1.2 (0.9) 1.4 (0.9) 1.1 (1.0)
Maternal BMI 29 (5) 29 (5) 29 (5)
Note: Appetite hormones and energy regulators were examined by sex
and using the 95th percentile cut-off for obesity; IDF criteria used to
calculate cutoff values for each metabolic risk factor. Values represent
mean (SD), unless indicated otherwise. *Values statistically different by
sex at P < .05, **P < .01, ***P < .001.
Abbreviation: No., abbreviation for number.
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Higher BMI at 10 y was directly related to an increase in meta-
bolic risk (β = 0.26, P < .001). In addition, BMIz-10y related to an
increase in HOMA-IR (β = 0.24, P < .001) and L:A (β = 0.29, P < .001).
In turn, an increase in HOMA-IR and an increase in L:A related to
increased metabolic risk (β = 0.31, P < .001 and β = 0.21, P < .001,
respectively). An increase in L:A was also associated with increased
HOMA-IR (β = 0.31, P < .001). BMIz-10y was not related to ghrelin at
16 y, but an increase in ghrelin was related to a decrease in HOMA-IR
(β = −0.23, P < .001).
Female sex was significantly related to higher ghrelin levels
(β = 0.09, P = .02), higher L:A (β = 0.35, P < .001), and greater meta-
bolic risk (β = 0.13, P < .001). Age was negatively related to ghrelin
levels (β = −0.13, P = .001) and HOMA-IR (β = 0.08, P = .01), and
maternal BMI was related to BMIz-10y (β = 0.25, P < .001). The final
model explained 39% of the variance in metabolic risk.
3.1.3 | Test of indirect effects
The significant indirect effects included (all P < .001): BMIz-10y à L:A
à metabolic risk (β = 0.06); BMIz-10y à HOMA à metabolic risk
(β = 0.07); BMIz-10y à L:A à HOMA à metabolic risk (β = 0.03).
Total indirect effects were 0.17.
4 | DISCUSSION
This study examined potential metabolic pathways by which a higher
childhood weight status might contribute to increased metabolic risk
among adolescents. We found multiple metabolic pathways mediated
by adipokines and insulin resistance. First, an increase in weight status
at age 10 y directly related to increased number of risk factors for the
metabolic syndrome at 16 y. Second, weight status was indirectly
related to an increase in metabolic risk through both leptin/
adiponectin ratio and insulin resistance. Third, we found that insulin
resistance partially mediated the relation between leptin/adiponectin
ratio and ghrelin and metabolic risk. These findings show the deleteri-
ous effect of higher childhood weight status on adolescent metabolic
health.
In this adolescent cohort, we found higher levels of leptin and
ratios of leptin/adiponectin among females than males, but not of
ghrelin. For risk factors comprising metabolic risk, we found that
males more than females had elevated blood pressure and elevated
glucose, yet females had lower HDL and greater abdominal obesity
compared to males. In fact, half of females in our study were classified
as having central obesity. When considering all factors, we found that
females had higher metabolic risk. These findings are concerning and
provides evidence of the disparities in cardiovascular and car-
diometabolic health among females in this setting. Others have found
similar findings.14,15 Furthermore, in light of the pathways illustrated
by Lucasson et al. (see Figure 1), and controlling for sex, we observed
that higher ratios of leptin/adiponectin worsened insulin resistance,
which is in line with the functions of leptin (pro-inflammatory) and
adiponectin (anti-inflammatory).8 Similarly, Schutte and colleagues
found a positive relationship between leptin with insulin resistance in
a study of 115 women.8 There are, however, other biological mecha-
nisms beyond the scope of this study that may play a role in the path-
way from child obesity to metabolic risk during adolescence. For
instance, appetite hormone dysregulation could have contributed to
increased caloric intake or appetite, and in turn increase risk for obe-
sity, which increased risk for insulin resistance. Factors related to
appetite hormone regulation most likely include lifestyle behaviors
such as sleep, dietary patterns and physical activity.
We found that increased weight status in childhood predicted poor
metabolic health in adolescence, which is consistent with the develop-
mental origins of health and disease. Moreover, our findings elucidate
mechanisms by which childhood obesity may be connected to appetite
hormone regulation, insulin resistance, and metabolic risk. In a prior
study in the same cohort, we also found evidence to support the nega-
tive impact of early onset obesity (measured at 5 y) on adolescent meta-
bolic health.16 Increased weight status at age 10 y predicted an increase
in the leptin/adiponectin ratio at 16 years old, which we expected,
given that levels of leptin (positively) and adiponectin (negatively) have
been associated with increased body mass index in children.9 In turn,
the leptin/adiponectin ratio was positively associated with an increased
risk for poor metabolic health. In addition, children with higher weight
status were prone to insulin resistance and, in turn, at risk for poor met-
abolic health, consistent with the hypothesis that insulin resistance is
the underlying cause of metabolic syndrome.17 In this study, these path-
ways accounted for almost half of the variance in metabolic risk. Future
research could include lifestyle behaviors known to be associated with
metabolic risk, such as sleep, diet, and physical activity, for a more com-
prehensive understanding of the biological and behavioral mechanisms
related to metabolic syndrome.
Another unique finding is that increased ghrelin concentration
related to a decrease in insulin resistance, whereas leptin/adiponectin
F IGURE 3 Pathways linking child
weight status to risk for metabolic
syndrome in a cohort of Chilean
adolescents (n = 679); Model fit:
CFI = 0.97, RMSEA = 0.05,
SRMR = 0.03, R-square = 0.38, total
indirect effects = 0.17. Note: Model
controls for maternal BMI, sex,
and age
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ratio was related to an increase in insulin resistance. These findings
differ slightly from the framework developed by Lucasson et al.
(Figure 1), as our findings suggest that ghrelin and leptin are con-
nected to insulin resistance. In addition, Klok and colleagues have pro-
posed that leptin and ghrelin systems function independently of each
other in the control of energy homeostasis.3 Our findings support this
notion, given that child weight status did not relate to ghrelin during
adolescence but did relate to an increased leptin/adiponectin ratio.
Furthermore, our findings are consistent with research showing high
leptin in individuals with obesity, which suggests the phenomenon of
leptin resistance.18
This study has some limitations to consider. The sample of Chil-
ean adolescents was not representative of the Chilean adolescent
population, as most were from low- to middle-income backgrounds in
urban Santiago. Also, adolescents were recruited as infants to partici-
pate in an iron deficiency anemia trial. Inclusion criteria for study
recruitment required that infants were term, healthy infants and
weighed ≥3 kg at birth. Caution is needed when attempting to gener-
alize to a larger population. Nevertheless, findings may be equally rel-
evant given the high prevalences of obesity, type 2 diabetes, and
cardiovascular disease among individuals from low middle socioeco-
nomic status, as estimated by the Chilean National Health Survey.19
Another limitation is the cross-sectional nature of data on car-
diometabolic biomarkers, which were not measured during prior
assessments of the cohort. This limits the ability to draw conclusions
related to the temporality of metabolic pathways. Future studies are
needed to consider mechanisms over time.
5 | CONCLUSIONS
To our knowledge, this is one of the first studies to illustrate the con-
nection of childhood obesity to metabolic pathways involving appetite
hormone regulation and metabolic risk during adolescence. Increased
weight status at 10 y directly and indirectly increased risk for meta-
bolic syndrome among adolescents via metabolic pathways that
included appetite hormones and insulin resistance. These findings not
only demonstrate the harmful role of childhood obesity on adolescent
risk for metabolic syndrome but also highlight the independent role of
ghrelin as a protective factor for insulin resistance. Childhood inter-
ventions are needed to attenuate the harmful role of childhood over-
weight/obesity on adolescent metabolic health. Further research is
needed to gain a better understanding of the independent role of
ghrelin in metabolic risk as well as behavioral factors (ie, sleep, diet,
physical activity) that play a role in inflammation and metabolic risk.
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